Identification and validation of public neoantigen targets

In a survey of the human mutation database, we have identified a mechanism, which we term ‘structural capacitance’ that results in the de novo generation of microstructure in previously disordered regions. These elements of protein microstructure are implicated in the pathogenesis of a wide range of human diseases, including cancer, and can generate neoantigens – epitopes that break immune tolerance. The aim of this project is to use machine learning to identify novel neoantigens from known somatic mutations, characterise their biochemical, biophysical and structural properties, paving the way for development of neoantigen-focused immunotherapies, including targeted antibodies, and cellular therapies.